Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune...

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2020 May 15

PMID 32406487

Citations 6

Authors

Donald D Anthony

Mark S Sulkowski

Laura M Smeaton

Sofi Damjanovska

Carey L Shive

Corinne M Kowal

Daniel E Cohen

Debika Bhattacharya

Beverly L Alston-Smith

Ashwin Balagopal

David L Wyles

Affiliations

Soon will be listed here.

Abstract

Background: Hepatitis C virus (HCV) direct-acting antivirals are highly effective. Less is known about changes in markers of immune activation in persons with human immunodeficiency virus (HIV) in whom a sustained virologic response (SVR) is achieved.

Methods: We conducted a nonrandomized clinical trial of 12 or 24 weeks of paritaprevir-ritonavir-ombitasvir plus dasabuvir (PrOD) with or without ribavirin in persons with HCV-1/HIV coinfection suppressed with antiretroviral therapy. Plasma HCV, soluble CD14 (sCD14), interferon-inducible protein 10, soluble CD163 (sCD163), interleukin 6 (IL-6), interleukin 18, monocyte chemoattractant protein (MCP-1), autotaxin (ATX), and Mac2-binding protein (Mac2BP) were measured over 48 weeks.

Results: Participants were treated with PrOD for 12 (n = 9) or 24 (n = 36) weeks; the SVR rate at 12 weeks was 93%. At baseline, cirrhosis was associated with higher ATX and MCP-1, female sex with higher ATX and IL-6, older age with higher Mac2BP, higher body mass index with higher ATX, and HIV-1 protease inhibitor use with higher sCD14 levels. In those with SVR, interferon-inducible protein 10, ATX, and Mac2BP levels declined by week 2, interleukin 18 levels declined by the end of treatment, sCD14 levels did not change, and sCD163, MCP-1, and IL-6 levels changed at a single time point.

Conclusions: During HIV/HCV coinfection, plasma immune activation marker heterogeneity is in part attributable to age, sex, cirrhosis, body mass index, and/or type of antiretroviral therapy. HCV treatment with paritaprevir-ritonavir-ombitasvir plus dasabuvir is highly effective and is associated with variable rate and magnitude of decline in markers of immune activation.

Clinical Trials Registration: NCT02194998.

Citing Articles

Injecting drug use and hepatitis C virus infection independently increase biomarkers of inflammatory disease risk which are incompletely restored by curative direct-acting antiviral therapy.

Hearps A, Vootukuru N, Ebrahimnezhaddarzi S, Harney B, Boo I, Nguyen L Front Immunol. 2024; 15:1352440.

PMID: 38420130 PMC: 10899672. DOI: 10.3389/fimmu.2024.1352440.

Changes in Inflammatory Cytokines After Chronic Hepatitis C Treatment Among People Living With HIV.

Karimi-Sari H, Piggott D, Scully E, Ward K, Sutcliffe C, Sulkowski M Open Forum Infect Dis. 2024; 11(1):ofad623.

PMID: 38192382 PMC: 10773550. DOI: 10.1093/ofid/ofad623.

Prodrug Therapies for Infectious and Neurodegenerative Diseases.

Markovic M, Deodhar S, Machhi J, Yeapuri P, Saleh M, Edagwa B Pharmaceutics. 2022; 14(3).

PMID: 35335894 PMC: 8953076. DOI: 10.3390/pharmaceutics14030518.

Variable Normalization of Naïve CD4+ Lymphopenia and Markers of Monocyte and T Cell Activation over the Course of Direct-Acting Anti-Viral Treatment of Chronic Hepatitis C Virus Infection.

Auma A, Shive C, Kostadinova L, Anthony D Viruses. 2022; 14(1).

PMID: 35062255 PMC: 8780994. DOI: 10.3390/v14010050.

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients.

Brochado-Kith O, Martinez I, Berenguer J, Gonzalez-Garcia J, Salguero S, Sepulveda-Crespo D Front Immunol. 2021; 12:723196.

PMID: 34497613 PMC: 8419228. DOI: 10.3389/fimmu.2021.723196.

References

Veenhuis R, Astemborski J, Chattergoon M, Greenwood P, Jarosinski M, Moore R . Systemic Elevation of Proinflammatory Interleukin 18 in HIV/HCV Coinfection versus HIV or HCV Monoinfection. Clin Infect Dis. 2016; 64(5):589-596. PMC: 5850551. DOI: 10.1093/cid/ciw771. View

Wijarnpreecha K, Chesdachai S, Jaruvongvanich V, Ungprasert P . Hepatitis C virus infection and risk of Parkinson's disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017; 30(1):9-13. DOI: 10.1097/MEG.0000000000000991. View

Ghany M, Morgan T . Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2019; 71(2):686-721. PMC: 9710295. DOI: 10.1002/hep.31060. View

Umemura T, Yamazaki T, Joshita S, Sugiura A, Fujimori N, Matsumoto A . Quantitative analysis of serum chemokines associated with treatment failure of direct-acting antivirals in chronic hepatitis C. Cytokine. 2018; 111:357-363. DOI: 10.1016/j.cyto.2018.10.004. View

Sulkowski M, Moore R, Mehta S, Chaisson R, Thomas D . Hepatitis C and progression of HIV disease. JAMA. 2002; 288(2):199-206. DOI: 10.1001/jama.288.2.199. View

Yamazaki T, Joshita S, Umemura T, Usami Y, Sugiura A, Fujimori N . Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C. PLoS One. 2018; 13(4):e0195632. PMC: 5884565. DOI: 10.1371/journal.pone.0195632. View

Serti E, Chepa-Lotrea X, Kim Y, Keane M, Fryzek N, Liang T . Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. Gastroenterology. 2015; 149(1):190-200.e2. PMC: 4523392. DOI: 10.1053/j.gastro.2015.03.004. View

Rockstroh J, Orkin C, Viani R, Wyles D, Luetkemeyer A, Lazzarin A . Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2. Open Forum Infect Dis. 2017; 4(3):ofx154. PMC: 5597897. DOI: 10.1093/ofid/ofx154. View

Simmons B, Saleem J, Heath K, Cooke G, Hill A . Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response. Clin Infect Dis. 2015; 61(5):730-40. PMC: 4530725. DOI: 10.1093/cid/civ396. View

10.

Hunt P, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N . Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014; 210(8):1228-38. PMC: 4192038. DOI: 10.1093/infdis/jiu238. View

11.

Drazilova S, Gazda J, Janicko M, Jarcuska P . Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Can J Gastroenterol Hepatol. 2018; 2018:6150861. PMC: 6110000. DOI: 10.1155/2018/6150861. View

12.

Cacoub P, Geffray L, Rosenthal E, Perronne C, Veyssier P, Raguin G . Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis. 2001; 32(8):1207-14. DOI: 10.1086/319747. View

13.

Zylberberg H, Pol S . Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clin Infect Dis. 1996; 23(5):1117-25. DOI: 10.1093/clinids/23.5.1117. View

14.

Yamazaki T, Joshita S, Umemura T, Usami Y, Sugiura A, Fujimori N . Association of Serum Autotaxin Levels with Liver Fibrosis in Patients with Chronic Hepatitis C. Sci Rep. 2017; 7:46705. PMC: 5397977. DOI: 10.1038/srep46705. View

15.

Tenorio A, Zheng Y, Bosch R, Krishnan S, Rodriguez B, Hunt P . Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014; 210(8):1248-59. PMC: 4192039. DOI: 10.1093/infdis/jiu254. View

16.

Sandler N, Wand H, Roque A, Law M, Nason M, Nixon D . Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011; 203(6):780-90. PMC: 3071127. DOI: 10.1093/infdis/jiq118. View

17.

Mascia C, Vita S, Zuccala P, Marocco R, Tieghi T, Savinelli S . Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon. PLoS One. 2017; 12(6):e0179400. PMC: 5499435. DOI: 10.1371/journal.pone.0179400. View

18.

Lopez-Cortes L, Trujillo-Rodriguez M, Baez-Palomo A, Benmarzouk-Hidalgo O, Dominguez-Molina B, Milanes-Guisado Y . Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients. J Infect Dis. 2018; 218(4):624-632. DOI: 10.1093/infdis/jiy136. View

19.

Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H . Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000; 356(9244):1800-5. DOI: 10.1016/s0140-6736(00)03232-3. View

20.

Wikby A, Nilsson B, Forsey R, Thompson J, Strindhall J, Lofgren S . The immune risk phenotype is associated with IL-6 in the terminal decline stage: findings from the Swedish NONA immune longitudinal study of very late life functioning. Mech Ageing Dev. 2006; 127(8):695-704. DOI: 10.1016/j.mad.2006.04.003. View